215 related articles for article (PubMed ID: 37833099)
1. A new era in the treatment of urothelial carcinoma.
Faltas B
Urol Oncol; 2023 Oct; 41(10):395-397. PubMed ID: 37833099
[TBL] [Abstract][Full Text] [Related]
2. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
[TBL] [Abstract][Full Text] [Related]
3. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zschäbitz S; Niegisch G
Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
[TBL] [Abstract][Full Text] [Related]
4. [Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
Matte P; Campedel L
Bull Cancer; 2022; 109(7-8):738-740. PubMed ID: 35606195
[No Abstract] [Full Text] [Related]
5. The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
Bertucci F; de Nonneville A; Finetti P; Cohendet A; Guille A; Mamessier E
Ann Oncol; 2024 May; 35(5):477-478. PubMed ID: 38364991
[No Abstract] [Full Text] [Related]
6. Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma.
Miron B; Geynisman DM
Eur Urol; 2022 Oct; 82(4):374-376. PubMed ID: 35752503
[No Abstract] [Full Text] [Related]
7. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
8. Erdafitinib's Road to Approval and Use in Urothelial Carcinoma.
Hanna K
Oncology (Williston Park); 2023 Jun; 37(6):260-261. PubMed ID: 37343205
[No Abstract] [Full Text] [Related]
9. Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
Benjamin DJ; Lythgoe MP; Rezazadeh A
BJU Int; 2023 Jun; 131(6):691-693. PubMed ID: 36877951
[No Abstract] [Full Text] [Related]
10. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Tilgener C; Bedke J
Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
[No Abstract] [Full Text] [Related]
11. Evolving systemic management of urothelial cancers.
Tan WS; Tan MY; Alhalabi O; Campbell MT; Kamat AM; Gao J
Curr Opin Oncol; 2023 May; 35(3):186-199. PubMed ID: 36966497
[TBL] [Abstract][Full Text] [Related]
12. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
Kim JH; Chang IH
Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
14. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
Khosla H; Bhatt S; Wang MJ; Gignac G; Mittal K; Patel J
J Oncol Pharm Pract; 2024 Jul; 30(5):941-944. PubMed ID: 38470473
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.
Bianchi A; von Deimling M; Pallauf M; Yanagisawa T; Kawada T; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Majdoub M; Motlagh RS; Pradere B; Karakiewicz PI; Cerruto MA; Antonelli A; Shariat SF
Expert Opin Pharmacother; 2023 Feb; 24(2):177-195. PubMed ID: 36440477
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
Taguchi S; Kawai T; Nakagawa T; Kume H
BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
[No Abstract] [Full Text] [Related]
17. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
Rexer H; Ohlmann CH; Gschwend J;
Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
[No Abstract] [Full Text] [Related]
18. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
[No Abstract] [Full Text] [Related]
19. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
[TBL] [Abstract][Full Text] [Related]
20. Contemporary Systemic Therapies in Urothelial Carcinoma.
Zhang JH; Starr SL; Chamie K
Urology; 2023 Apr; 174():150-158. PubMed ID: 36682700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]